PTC Therapeutics (PTCT) Stock Statistics & Valuation Metrics

PTC Therapeutics has a market cap or net worth of $3.82B. The enterprise value is $2.69B.

PTC Therapeutics has 79,257,020 shares outstanding. The number of shares has decreased by -2.65% in one year.

PTC Therapeutics’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is -26.31%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, PTC Therapeutics had revenue of 806.78M and earned -363.30M in profits. Earnings per share was -4.73.

In the last 12 months, operating cash flow was 691.65M and capital expenditures 52.59M, giving a free cash flow of 744.24M billion.

PTC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

PTC Therapeutics upcoming earnings date is Jul 31, 2025, After Close (Confirmed).

PTC Therapeutics as a current ratio of 2.35, with Debt / Equity ratio of -209.74%

In the past 12 months, PTC Therapeutics has paid 176.00K in taxes.

PTC Therapeutics EV to EBITDA ratio is -25.55, with an EV/FCF ratio of -26.96.

PTC Therapeutics has $2.03B in cash and marketable securities with $389.62M in debt, giving a net cash position of -$1.64B billion.

Gross margin is 96.52%, with operating margin of -37.50%, and net profit margin of -45.03%.

The average price target for PTC Therapeutics is $62.08, which is 11.43% higher than the current price. The consensus rating is Moderate Buy